Accelerated Community Oncology Research Network
17
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
High Risk
Score: 80/100
41.2%
7 terminated/withdrawn out of 17 trials
58.8%
-27.7% vs industry average
6%
1 trials in Phase 3/4
160%
16 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (17)
Trial of Dasatinib Plus Ixabepilone in 2nd or 3rd Line Metastatic Breast Cancer
Role: lead
1st or 2nd Line MBC (Metastatic Breast Cancer) With Previous Avastin (Bevacizumab) Therapy
Role: lead
Everolimus Dose Finding Study for Stage IV or Recurrent Cervical Cancer
Role: lead
Phase 2b Study of Cetuximab With Platinum-Based Chemo as First Line Treatment of Recurrent or Advanced NSCLC
Role: lead
Oral Topotecan to Treat Recurrent or Persistent Solid Tumors
Role: lead
Randomized Study of Sorafenib Dose Escalation in Patients With Previously Untreated Metastatic Renal Cell Carcinoma
Role: lead
Phase II Trial of Capecitabine With Fulvestrant for Postmenopausal Women With Hormone Receptor Positive Metastatic Breast Cancer
Role: lead
Panitumumab, Paclitaxel, Carboplatin and 5FU in the Treatment of Potentially Resectable Gastroesophageal Adenocarcinoma
Role: lead
Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma
Role: lead
Bevacizumab With Abraxane in Patients With Recurrent Ovarian/ Peritoneal Cancer
Role: lead
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
Role: lead
Phase II Study Alimta and Gemzar + Avastin as First Line Chemotherapy for Elderly Patients With Stage IIIB/IV NSCLC
Role: lead
Study of Gamma Interfereon in Metastatic Colorectal Carcinoma
Role: lead
A Phase I Trial Evaluating mFOLFOX6 and Avastin With Nexavar as First-Line Treatment for Metastatic Colorectal Cancer
Role: lead
Mitoxantrone, Prednisone Plus Sorafenib in Taxane-Refractory Metastatic Hormone Refractory Prostate Cancer (HRPC)
Role: lead
Treating Chronic Insomnia in Breast Cancer Patients
Role: lead
Phase I, Dosage-finding and PK Study of IV Topotecan and Erlotinib With Refractory Solid Tumors
Role: lead
All 17 trials loaded